Mohamad Jawhar
Overview
Explore the profile of Mohamad Jawhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niedoszytko M, Gorska A, Brockow K, Bonadonna P, Lange M, Kluin-Nelemans H, et al.
Allergy
. 2024 Apr;
79(9):2470-2481.
PMID: 38651829
Background: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies...
2.
Greiner G, Witzeneder N, Klein K, Tangermann S, Kodajova P, Jaeger E, et al.
Blood
. 2023 Dec;
143(11):1006-1017.
PMID: 38142424
Systemic mastocytosis (SM) is defined by the expansion and accumulation of neoplastic mast cells (MCs) in the bone marrow (BM) and extracutaneous organs. Most patients harbor a somatic KIT D816V...
3.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, et al.
Haematologica
. 2023 Nov;
109(5):1426-1438.
PMID: 37916386
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a...
4.
Altrock E, Sens-Albert C, Hofmann F, Riabov V, Schmitt N, Xu Q, et al.
Stem Cell Res Ther
. 2023 Jun;
14(1):156.
PMID: 37287056
Background: Robust and reliable in vitro and in vivo models of primary cells are necessary to study the pathomechanisms of Myelodysplastic Neoplasms (MDS) and identify novel therapeutic strategies. MDS-derived hematopoietic...
5.
Buschhorn L, Odoni D, Geuder J, Odinius T, Wagner C, Jilg S, et al.
Haematologica
. 2023 May;
108(11):3125-3130.
PMID: 37165843
No abstract available.
6.
Xu Q, Streuer A, Jann J, Altrock E, Schmitt N, Flach J, et al.
Nat Commun
. 2023 Mar;
14(1):1497.
PMID: 36932114
Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with...
7.
Lubke J, Schwaab J, Christen D, Elberink H, Span B, Niedoszytko M, et al.
J Allergy Clin Immunol Pract
. 2022 Nov;
11(2):581-590.e5.
PMID: 36403897
Background: Organomegaly, including splenomegaly, hepatomegaly, and/or lymphadenopathy, are important diagnostic and prognostic features in patients with cutaneous mastocytosis (CM) or systemic mastocytosis (SM). Objectives: To investigate the prevalence and prognostic...
8.
Kennedy V, Perkins C, Reiter A, Jawhar M, Lubke J, Kluin-Nelemans H, et al.
Blood Adv
. 2022 Sep;
7(9):1713-1724.
PMID: 36094848
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the...
9.
Riffel J, Lubke J, Naumann N, Kreil S, Metzgeroth G, Fabarius A, et al.
Sci Rep
. 2022 Aug;
12(1):14228.
PMID: 35987779
Systemic mastocytosis (SM) is characterized by multifocal accumulation of neoplastic mast cells (MCs), predominately affecting the bone marrow (BM). Imaging with computed tomography (CT) is used for assessment of bone...
10.
Schneeweiss-Gleixner M, Filik Y, Stefanzl G, Berger D, Sadovnik I, Bauer K, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804842
In most patients with advanced systemic mastocytosis (AdvSM), neoplastic mast cells (MC) express D816V. However, despite their disease-modifying potential, KIT D816V-targeting drugs, including midostaurin and avapritinib, may not produce long-term...